[go: up one dir, main page]

PE20011177A1 - LAS 5-ALQUILPIRIDO [2,3-d] PIRIMIDINAS SON INHIBIDORAS DE LAS CINASAS DE TIROSINA Y QUE DEPENDEN DE LA CICLINA - Google Patents

LAS 5-ALQUILPIRIDO [2,3-d] PIRIMIDINAS SON INHIBIDORAS DE LAS CINASAS DE TIROSINA Y QUE DEPENDEN DE LA CICLINA

Info

Publication number
PE20011177A1
PE20011177A1 PE2001000216A PE2001000216A PE20011177A1 PE 20011177 A1 PE20011177 A1 PE 20011177A1 PE 2001000216 A PE2001000216 A PE 2001000216A PE 2001000216 A PE2001000216 A PE 2001000216A PE 20011177 A1 PE20011177 A1 PE 20011177A1
Authority
PE
Peru
Prior art keywords
alkyl
pyrimidines
methyl
alkylpyride
cycline
Prior art date
Application number
PE2001000216A
Other languages
English (en)
Inventor
Richard John Booth
Scott Norman Vanderwel
Peter Laurence Toogood
Ellen Myra Dobrusin
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20011177A1 publication Critical patent/PE20011177A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A DERIVADOS DE 5-ALQUILPIRIDO [2,3-d] PIRIMIDINAS DE FORMULA I DONDE R2 ES H, ALQUILO, CARBOCICLICO C3-C7; R3 ES H, ALQUILO, ALCOXI, HALOGENO, TRIFLUOROMETILO, ALQUINILO, ALQUENILO, ENTRE OTROS; Y ES N, CR7; R9 ES ALQUILO, HALOALQUILO, ARILO; X Y Z SON H, HALOGENO, ALQUILO, ALCOXI, TRIFLUOROMETILO, HIDROXI, NITRILO, NR4R5, ENTRE OTROS; R4 Y R5 SON H, ALQUILO, ALQUENILO, ALQUINILO, (CH2)nAr, ARILALQUILO, ARILO, HETEROARILO, HETEROARILALQUILO, ENTRE OTROS; R7 ES NR4R5, N(O)R4R5, OH, OR4, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 8-CICLOPENTIL-5-METIL-2-(4-PIPERAZIN-1-IL-FENILAMINO)-8H-PIRIDO[2,3]PIRIMIDIN-7-ONA,8-(1-METILETIL)-5-METIL-2-(4-PIPERAZIN-1-IL-FENILAMINO)-8H-PIRIDO[2,3]PIRIMIDIN-7-ONA,8-CICLOPENTIL-5-METIL-2-(4-FLUORO-3-METIL-FENILAMINO)-8H-PIRIDO[2,3]PIRIMIDIN-7-ONA, ENTRE OTROS. LOS COMPUESTOS DE 5-ALQUILPIRIDO [2,3-d] PIRIMIDINAS SON INHIBIDORES DE TIROSINA CINASAS DEPENDIENTES DE CICLINA (Cdk) Y SON UTILES PARA EL TRATAMIENTO DE INFLAMACION, ENFERMEDADES PROLIFERATIVAS, CANCER, RESTENOSIS, ENFERMEDADES NEURODEGENERATIVAS
PE2001000216A 2000-03-06 2001-03-05 LAS 5-ALQUILPIRIDO [2,3-d] PIRIMIDINAS SON INHIBIDORAS DE LAS CINASAS DE TIROSINA Y QUE DEPENDEN DE LA CICLINA PE20011177A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18712400P 2000-03-06 2000-03-06

Publications (1)

Publication Number Publication Date
PE20011177A1 true PE20011177A1 (es) 2001-11-23

Family

ID=22687699

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000216A PE20011177A1 (es) 2000-03-06 2001-03-05 LAS 5-ALQUILPIRIDO [2,3-d] PIRIMIDINAS SON INHIBIDORAS DE LAS CINASAS DE TIROSINA Y QUE DEPENDEN DE LA CICLINA

Country Status (36)

Country Link
EP (1) EP1268476A1 (es)
JP (1) JP2003528101A (es)
KR (1) KR20020075805A (es)
CN (1) CN1422268A (es)
AP (1) AP2002002643A0 (es)
AR (1) AR034119A1 (es)
AU (1) AU2001233028A1 (es)
BG (1) BG107161A (es)
BR (1) BR0109056A (es)
CA (1) CA2401368A1 (es)
CO (1) CO5280200A1 (es)
CR (1) CR6736A (es)
CZ (1) CZ20022929A3 (es)
DZ (1) DZ3308A1 (es)
EA (1) EA200200802A1 (es)
EE (1) EE200200506A (es)
GT (1) GT200100037A (es)
HN (1) HN2001000040A (es)
HR (1) HRP20020798A2 (es)
HU (1) HUP0300136A2 (es)
IL (1) IL151480A0 (es)
IS (1) IS6524A (es)
MA (1) MA26881A1 (es)
MX (1) MXPA02008535A (es)
NO (1) NO20024235L (es)
NZ (1) NZ520962A (es)
OA (1) OA12227A (es)
PA (1) PA8513201A1 (es)
PE (1) PE20011177A1 (es)
PL (1) PL358271A1 (es)
SK (1) SK12472002A3 (es)
SV (1) SV2001000338A (es)
TN (1) TNSN01036A1 (es)
WO (1) WO2001070741A1 (es)
YU (1) YU66502A (es)
ZA (1) ZA200207110B (es)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
EP2404603A1 (en) 2000-10-23 2012-01-11 Glaxosmithkline LLC Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases
AU2002256615B2 (en) * 2001-02-12 2007-09-13 F. Hoffmann-La Roche Ag 6-substituted pyrido-pyrimidines
EP1364950A4 (en) * 2001-02-26 2005-03-09 Tanabe Seiyaku Co Pyridopyrimidine and naphthyridine derivatives
AU2002324450A1 (en) * 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidines and uses thereof
US20030100572A1 (en) * 2001-06-21 2003-05-29 Ariad Pharmaceuticals,Inc. Novel pyridopyrimidones and uses thereof
KR20060111716A (ko) 2002-01-22 2006-10-27 워너-램버트 캄파니 엘엘씨 2-(피리딘-2-일아미노)-피리도[2,3-ｄ]피리미딘-7-온
US7629350B2 (en) 2002-04-19 2009-12-08 Smithkline Beecham Corporation Compounds
WO2004011456A1 (en) 2002-07-31 2004-02-05 Danter Wayne R Protein tyrosine kinase inhibitors
WO2004033446A1 (en) 2002-10-09 2004-04-22 Danter Wayne R Protein tyrosine kinase inhibitors
MXPA05007503A (es) * 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
PL1648889T3 (pl) * 2003-07-11 2009-03-31 Warner Lambert Co Sól izetionian selektywnego inhibitora CDK4
EP1663204B1 (en) * 2003-08-29 2014-05-07 Exelixis, Inc. C-kit modulators and methods of use
JP4616839B2 (ja) 2003-11-13 2011-01-19 エフ．ホフマン−ラ ロシュ アーゲー ヒドロキシアルキル置換ピリド−７−ピリミジン−７−オン類
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
WO2006021547A1 (de) * 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinone als plk (polo like kinase) inhibitoren
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
US7652041B2 (en) 2005-01-14 2010-01-26 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity
US20080096905A1 (en) 2005-03-25 2008-04-24 Glaxo Group Limited Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives
PE20100741A1 (es) 2005-03-25 2010-11-25 Glaxo Group Ltd COMPUESTOS DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA COMO INHIBIDORES DE QUINASA p38
TWI389690B (zh) 2005-03-25 2013-03-21 Glaxo Group Ltd 新穎化合物（一）
WO2006110298A2 (en) 2005-03-25 2006-10-19 Glaxo Group Limited 8-alkyl/aryl-4-aryl-2-n- (alkylamino)-n'-substituted-n'-cyanoguanidino-8h-pyrido[2,3-d]pyrimidin-7-one compounds and use thereof
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
FR2887882B1 (fr) * 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
CN102746298A (zh) * 2005-10-07 2012-10-24 埃克塞里艾克西斯公司 PI3Kα的吡啶并嘧啶酮抑制剂
NZ594628A (en) * 2005-10-07 2013-04-26 Exelixis Inc PYRIDOPYRIMIDINONE INHIBITORS OF PI3Ka
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
WO2008032162A1 (en) 2006-09-15 2008-03-20 Pfizer Products Inc. Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
BRPI0715566A2 (pt) * 2006-10-16 2013-07-02 Gpc Biotech Inc composto, prà-droga, composiÇço farmacÊutica, uso de um composto, mÉtodo para inibir a proliferaÇço de cÉlulas e mÉtodo para sintetizar um composto
US20080114007A1 (en) * 2006-10-31 2008-05-15 Player Mark R 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
FR2910813B1 (fr) 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
US8138191B2 (en) 2007-01-11 2012-03-20 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
JP5374492B2 (ja) * 2007-04-03 2013-12-25 アレイ バイオファーマ、インコーポレイテッド 受容体チロシンキナーゼ阻害薬としてのイミダゾ［１，２−ａ］ピリジン化合物
HRP20161536T1 (hr) 2007-06-15 2016-12-30 Msd K.K. Derivat bicikloanilina
EP2185559A1 (en) 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
CA2709202C (en) 2007-12-19 2013-04-23 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
US8466151B2 (en) 2007-12-26 2013-06-18 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
EP2100894A1 (en) * 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
WO2009126584A1 (en) 2008-04-07 2009-10-15 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
WO2010039740A1 (en) 2008-09-30 2010-04-08 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα AND MTOR
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
WO2011044535A2 (en) * 2009-10-09 2011-04-14 Afraxis, Inc. 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
KR101754664B1 (ko) 2009-12-18 2017-07-06 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 치환된 피리도〔2,3-ｄ〕피리미딘-7(8ｈ)-온스 및 이의 치료 용도
AR080151A1 (es) 2010-02-09 2012-03-14 Exelixis Inc Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia
EP3235818A3 (en) 2010-04-01 2018-03-14 Critical Outcome Technologies, Inc. Compounds for the treatment of hiv
PL2600719T3 (pl) * 2010-08-05 2015-03-31 Univ Temple 2-Podstawione 8-alkilo-7-okso-7,8-dihydropirydo[2,3-d]pirymidyno-6-karbonitryle oraz ich zastosowania
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
EP2646448B1 (en) 2010-11-29 2017-08-30 OSI Pharmaceuticals, LLC Macrocyclic kinase inhibitors
KR20160035613A (ko) 2011-03-23 2016-03-31 암젠 인크 Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
KR102027598B1 (ko) * 2011-05-17 2019-10-01 프린시피아 바이오파마, 인코퍼레이티드 타이로신 키나아제 저해제
JP2015511245A (ja) * 2012-02-23 2015-04-16 アッヴィ・インコーポレイテッド ピリドピリミジノン系キナーゼ阻害薬
PT2958916T (pt) * 2013-02-21 2018-11-21 Pfizer Formas sólidas de um inibidor de cdk4/6 seletivo
US20150031699A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
CN105294681B (zh) 2014-07-26 2017-07-07 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
TWI646094B (zh) * 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
ES2876411T3 (es) 2016-08-15 2021-11-12 Pfizer Inhibidores de piridopirimdinona CDK2/4/6
AU2018229148B2 (en) * 2017-03-03 2022-08-04 Auckland Uniservices Limited FGFR kinase inhibitors and pharmaceutical uses
CA3089592A1 (en) 2018-02-15 2019-08-22 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
WO2020114519A1 (zh) * 2018-12-07 2020-06-11 杭州英创医药科技有限公司 作为cdk-hdac双通路抑制剂的杂环化合物
CN112759589B (zh) * 2019-11-01 2022-04-08 暨南大学 嘧啶并吡啶酮类化合物及其应用
WO2021108803A1 (en) 2019-11-26 2021-06-03 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as jak inhibitors
JP7756374B2 (ja) * 2021-03-08 2025-10-20 曁南大学 ピリドピリミジン系化合物及びその使用
WO2022258023A1 (zh) * 2021-06-09 2022-12-15 郑州同源康医药有限公司 用作cdk激酶抑制剂的化合物及其应用
CN117720531A (zh) * 2022-09-16 2024-03-19 华东师范大学 作为rsk抑制剂的吡啶酮并嘧啶衍生物及其应用
WO2024099403A1 (zh) * 2022-11-10 2024-05-16 北京普祺医药科技股份有限公司 一种具有软药性质的硫醚类化合物、药物组合物及其用途
WO2024107730A1 (en) * 2022-11-14 2024-05-23 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
DE69839338T2 (de) * 1997-02-05 2008-07-10 Warner-Lambert Company Llc Pyrido (2,3-d) pyrimidine und 4-amino-pyrimidine als inhibitoren der zellulären proliferation
ES2310039T3 (es) * 1998-05-26 2008-12-16 Warner-Lambert Company Llc Pirimidinas biciclicas y 3,4-dihidropirimidinas biciclicas como inhibidores de la proliferacion celular.

Also Published As

Publication number Publication date
TNSN01036A1 (en) 2005-11-10
SV2001000338A (es) 2001-11-30
MA26881A1 (fr) 2004-12-20
HN2001000040A (es) 2001-09-06
CZ20022929A3 (cs) 2003-02-12
JP2003528101A (ja) 2003-09-24
AR034119A1 (es) 2004-02-04
KR20020075805A (ko) 2002-10-05
PL358271A1 (en) 2004-08-09
AP2002002643A0 (en) 2002-12-31
PA8513201A1 (es) 2003-06-30
CN1422268A (zh) 2003-06-04
IS6524A (is) 2002-08-23
YU66502A (sh) 2005-09-19
MXPA02008535A (es) 2002-12-13
WO2001070741A1 (en) 2001-09-27
CO5280200A1 (es) 2003-05-30
ZA200207110B (en) 2003-12-04
HUP0300136A2 (en) 2003-05-28
NZ520962A (en) 2003-09-26
HRP20020798A2 (en) 2004-02-29
CR6736A (es) 2004-03-10
AU2001233028A1 (en) 2001-10-03
IL151480A0 (en) 2003-04-10
OA12227A (en) 2004-03-18
NO20024235L (no) 2002-11-05
GT200100037A (es) 2002-03-04
EP1268476A1 (en) 2003-01-02
NO20024235D0 (no) 2002-09-05
SK12472002A3 (sk) 2003-04-01
BR0109056A (pt) 2003-06-03
DZ3308A1 (fr) 2001-09-27
EE200200506A (et) 2004-02-16
CA2401368A1 (en) 2001-09-27
EA200200802A1 (ru) 2003-02-27
BG107161A (en) 2003-06-30

Similar Documents

Publication Publication Date Title
PE20011177A1 (es) LAS 5-ALQUILPIRIDO [2,3-d] PIRIMIDINAS SON INHIBIDORAS DE LAS CINASAS DE TIROSINA Y QUE DEPENDEN DE LA CICLINA
EA200500721A1 (ru) Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
PE20030975A1 (es) 2-(PIRIDIN-2-ILAMINO)-PIRIDO[2,3-d]PIRIMIDIN-7-ONAS
PE20021096A1 (es) Derivados de 4-amino-5-fenil-7-ciclobutil-pirrolo[2,3-d]pirimidina como inhibidores de la tirosina-cinasa igf-ir
PE20021010A1 (es) Derivados espirociclicos como inhibidores de fosfodiesterasa-7
UY27714A1 (es) 2 - heteroaril - pirimidinas inhibidoras de cdk, su preparación y su uso como medicamentos.
ECSP034831A (es) Derivados sustituidos de la 2-piridina ciclohexano-1,4-diamina
PE20030208A1 (es) Derivados de indirubina que contienen azufre, su preparacion y uso
MXPA02011426A (es) Derivados de b-carbolina utiles como inhibidores de fosfodiesterasa.
BR0206633A (pt) Derivados de 1-aril- ou 1-arilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6
ECSP024399A (es) Derivados de benzotiazol
ES2195785B1 (es) Nuevos derivados de piridazin-3(2h)-ona.
PA8609201A1 (es) Piridinonas sustituidas
HN2002000067A (es) Inhibidores de la rho - quinasa.
CU23148A3 (es) Compuestos azapoliciclicos condensados con arilo
ATE302775T1 (de) Carbolinderivate
PE20020594A1 (es) Derivados de indirubina aril-sustituidos, su preparacion y uso
SV2003001173A (es) 1-alquil o 1-cicloalquil-triazolo [4,3-a] quinazolin-5- onas como inhibidoras de fosfodiesterasa
BR0215151A (pt) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
PE20060504A1 (es) Derivados de pirimidina en el tratamiento de cancer
ECSP045156A (es) Derivados de indolilalquilamina como ligandos 5-hidroxitriptamina-6
ATE346067T1 (de) Carbolinderivate
ECSP034917A (es) Nuevos derivados de acido sulfonico
PA8572001A1 (es) Derivados de isoquinolina
PE42898A1 (es) Nuevos derivados de 2-(3h)-oxazolona

Legal Events

Date Code Title Description
FC Refusal